Bieging KT, Mello SS, Attardi LD
Identify the route and formulation
Blood 2005;106:1694702
All study participants were randomly assigned to an experimental treatment group that received subcutaneous injection of cagrilintide, once-weekly, in doses of either 0.3, 0.6, 1.2, 2.4, or 4.5 mg, as well as a one-daily 3.0 mg dose of liraglutide, and a volume matched placebo for control purposes
Medication Conflicts Because cagrilintide slows gastric emptying, it can change how oral medications are absorbed
Seahorse testing, for example, currently in the research phase, looks at ATP production and free phosphate production